Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Angelo Chimenti"'
Autor:
Alessandra Mangia, Valeria Piazzolla, Anna Giannelli, Egidio Visaggi, Nicola Minerva, Vincenzo Palmieri, Immacolata Carraturo, Domenico Potenza, Nicola Napoli, Gianfranco Lauletta, Vincenzo Tagarielli, Rosanna Santoro, Ernesto Piccigallo, Sergio De Gioia, Angelo Chimenti, Giuseppe Cuccorese, Antonio Metrangolo, Michele Mazzola, Ernesto Agostinacchio, Giuseppe Mennea, Carlo Sabbà, Marina Cela, Massimiliano Copetti, Ruggiero Losappio
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0215783 (2019)
Background and objectivesThe pangenotypic single tablet regimen of NS5B inhibitor sofobuvir (SOF) and NS5A inhibitor velpatasvir (VEL) is advised for 12 weeks in HCV-infected patients including those with compensated cirrhosis. Addition of ribavirin
Externí odkaz:
https://doaj.org/article/38669835eb1d495ab67368d7b9a91bf2
Autor:
Alessandra Mangia, Valeria Piazzolla, Anna Giannelli, Egidio Visaggi, Nicola Minerva, Vincenzo Palmieri, Immacolata Carraturo, Domenico Potenza, Nicola Napoli, Gianfranco Lauletta, Vincenzo Tagarielli, Rosanna Santoro, Ernesto Piccigallo, Sergio De Gioia, Angelo Chimenti, Giuseppe Cuccorese, Antonio Metrangolo, Michele Mazzola, Ernesto Agostinacchio, Giuseppe Mennea, Carlo Sabbà, Marina Cela, Massimiliano Copetti, Ruggiero Losappio
Publikováno v:
PLoS ONE, Vol 14, Iss 9, p e0223287 (2019)
[This corrects the article DOI: 10.1371/journal.pone.0215783.].
Externí odkaz:
https://doaj.org/article/90844ed692464d00a5ed970d856f7d89
Autor:
Giuseppe Mennea, Massimiliano Copetti, Ernesto Piccigallo, Alessandra Mangia, Domenico Potenza, Antonio Metrangolo, M. Cela, Giuseppe Cuccorese, Egidio Visaggi, Sergio De Gioia, Carlo Sabbà, Michele Mazzola, Rosanna Santoro, Nicola Napoli, Ruggiero Losappio, Gianfranco Lauletta, Vincenzo Tagarielli, Ernesto Agostinacchio, Nicola Minerva, Valeria Piazzolla, Immacolata Carraturo, Vincenzo Palmieri, A. Giannelli, Angelo Chimenti
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 5, p e0215783 (2019)
PLoS ONE, Vol 14, Iss 5, p e0215783 (2019)
Background and objectivesThe pangenotypic single tablet regimen of NS5B inhibitor sofobuvir (SOF) and NS5A inhibitor velpatasvir (VEL) is advised for 12 weeks in HCV-infected patients including those with compensated cirrhosis. Addition of ribavirin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bcd39f2d955f44d320f59c393781b17
https://doi.org/10.1371/journal.pone.0215783
https://doi.org/10.1371/journal.pone.0215783